Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis

Company Overview

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Key Stats

• Today's Range: 163.13 to 168.50
• 50-Day Range: 143.50 to 220
• 52-Week Range: 85 to 324
• Volume: 15,167 shs
• Average Volume: 45,010 shs
• Market Capitalization: £175.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FARN Stock Analysis - Frequently Asked Questions

How have FARN shares performed this year?

Faron Pharmaceuticals Oy's stock was trading at GBX 305 at the beginning of the year. Since then, FARN shares have decreased by 44.9% and is now trading at GBX 168.
View the best growth stocks for 2024 here.

How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Faron Pharmaceuticals Oy own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:FARN
• CUSIP: N/A
• CIK: N/A
• Web: www.faron.com
• Phone: +358-2-4695151
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-31,610,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -70.00%

Debt

• Debt-to-Equity Ratio: 922.55
• Current Ratio: 1.45
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: £-725,000.00
• Price / Sales: -242.43
• Cash Flow: GBX 8.40 per share
• Price / Cash Flow: 20.00
• Book Value: GBX 1 per share
• Price / Book: 168.00

Miscellaneous

• Outstanding Shares: 104,620,000
• Free Float: N/A
• Market Cap: £175.76 million
• Optionable: Not Optionable
• Beta: 0.36